• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Pirtobrutinib is safe and efficacious in the treatment of relapsed or refractory B-cell malignancies (BRUIN Trial)

byMichael PratteandTeddy Guo
March 18, 2021
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Bruton’s tyrosine kinase inhibitor pirtobrutinib showed efficacy in the treatment of relapsed or refractory B-cell malignancies such as chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom macroglobulinemia and marginal zone lymphoma.

2. Pirtobrutinib had a manageable safety profile, with few grade 3 or more adverse events.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Covalent Bruton’s tyrosine kinase inhibitors (BTKi) are a cornerstone in the treatment of B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia (WM), small lymphocytic lymphoma (SLL) and marginal zone lymphoma (MZL). However, recent data has shown that their efficacy is limited due to the development of resistance and intolerance. New in-class drugs, such as the BTKi, pirtobrutinib, are currently in development to produce agents with high selectivity and potency to overcome BTKi resistance. This first in-human, phase 1/2, open-label study sought to evaluate to safety and efficacy of the selective BTKi, pirtobrutinib. Overall, pirtobrutinib offered a good safety profile. No dose-limited toxicities were detected and the maximum tolerated dose was not reached. The majority of adverse events (87% of 1735 events) were grades 1-2. Amongst the grade 3 or higher adverse events that did occur, neutropenia was most common, and febrile neutropenia only occurred in five patients overall. No correlation was seen between pirtobrutinib exposure and frequency of grade 3 or higher adverse events. Amongst the patients evaluable for efficacy data, objective response rate (ORR) was 63% in those with CLL/SLL. The main limitation of this study is that the chronic, extended nature of some B-cell malignancies make it difficult to fully understand the long-term efficacy of pirtobrutinib. Similarly, this limits to assessment of its safety data when used for an extended period.

Click to read the study in The Lancet

Relevant Reading: Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia

In-Depth [randomized controlled trial]: This first-in-human, phase 1/2, open-label trial of the BTKi pirtobrutinib occurred in 27 sites across Australia, France, Italy, Poland, the UK and the USA. A total of 323 patients with refractory or relapsed B-cell malignancy were recruited in the safety population, and, amongst those, 269 in the efficacy population. Pirtobrutinib was administered once daily PO in 28-day cycles, at seven progressive dose levels: 25mg, 50mg, 100mg, 150mg, 200mg, 250mg and 300mg. The primary outcome for the phase 1 portion was determining the maximum tolerated dose of pirtobrutinib, while for phase 2 it was determining the ORR. Overall, no dose-limiting toxicities were observed (i.e., no maximum tolerated dose was reached). The majority of adverse events (87% of 1735) were grade 1/2. Neutropenia was the most common grade 3/4 adverse event, occurring in 10% of the 323 patients in this study. Only 5 patients (<1% of total) experienced febrile neutropenia. No correlation between pirtobrutinib exposure and adverse events was found. Atrial fibrillation/flutter, a serious safety concern in those taking BTKi’s, was seen in a total of two patients (<1% of total), and considered unrelated to study treatment. Among the 139 patients with either CLL or SLL, the ORR was 63% (95%CI 55-71). 88% of those patients remain on pirtobrutinib, with a median follow-up of 6 months (IQR 4-9). Of the 88 responders reported, only five discontinued treatment (four progressed and one electively discontinued). Amongst the 56 patients evaluable for efficacy with MCL, the ORR was 52% (38-65%). 57% of patients with MCL remain on pirtobrutinib, with a median follow-up of 6 months (IQR 3-9). In the 19 evaluable patients with WM, the ORR was 68%.

RELATED REPORTS

#VisualAbstract: Rituximab plus lenalidomide shows comparable survival compared to chemotherapy for CD20⁺ follicular lymphoma

Increased use of pediatric CT poses significant oncogenic risk [Classics Series]

CT scans increase the risk of malignancy in children and young adults [Classics Series]

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: b cell non hodgkin lymphomaB-cell lymphomabruton's tyrosine kinase (BTK)bruton's tyrosine kinase inhibitors (BTKi)chronic lymphocytic leukemiachronic lymphocytic leukemia (CLL)leukemialymphomamantle cellmantle cell lymphomamarginal zone lymphomaNon-Hodgkin Lymphomapirtobrutinibrelapsed mantle cell lymphomarelapsed or refractory mantle cell lymphomaWaldenström Macroglobulinemia
Previous Post

#VisualAbstract: Nivolumab plus ipilimumab is safe and effective for the treatment of advanced melanoma (CheckMate 218)

Next Post

Ketamine infusion significantly reduces depressive symptoms among adolescents with treatment-resistant depression

RelatedReports

#VisualAbstract: Chemoradiotherapy with carboplatin is more effective than cetuximab in head and neck squamous cell carcinoma
StudyGraphics

#VisualAbstract: Rituximab plus lenalidomide shows comparable survival compared to chemotherapy for CD20⁺ follicular lymphoma

October 19, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

Increased use of pediatric CT poses significant oncogenic risk [Classics Series]

August 15, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

CT scans increase the risk of malignancy in children and young adults [Classics Series]

August 15, 2022
Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma
Chronic Disease

Lisocabtagene maraleucel improves survival for relapsed or refractory large B-cell lymphoma

June 29, 2022
Next Post
Parents often unaware of adolescents’ suicidal thoughts

Ketamine infusion significantly reduces depressive symptoms among adolescents with treatment-resistant depression

Brain lesions on MRI linked with subsequent increased stroke risk

Association of intensive blood pressure control with magnetic resonance imaging biomarkers of Alzheimer's Disease

#VisualAbstract MRCN-003/CCTGMYX.1: Weekly carfilzomib, cyclophosphamide, and dexamethasone may be a safe and effective option for patients with relapsed/refractory multiple myeloma

#VisualAbstract MRCN-003/CCTGMYX.1: Weekly carfilzomib, cyclophosphamide, and dexamethasone may be a safe and effective option for patients with relapsed/refractory multiple myeloma

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Low-dose pirfenidone may be noninferior to standard dosing in patients with idiopathic pulmonary fibrosis
  • Protein-truncating variants in apolipoprotein B and PCSK9 genes associated with lower exposure to atherogenic LDL cholesterol and risk of coronary heart disease
  • College campus monkeypox outbreaks can be controlled with timely detection and isolation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options